ALSO NOTED: Sirna soars on new study; FDA rejects Namenda bid; Immunogen inks new licensing deal; and much more...

> A new study published in Nature Biotechnology confirms that Sirna Therapeutics technology may well form the basis of a new class of drugs -- sending its stock up 50 percent. Story

> Citing conflicting trial data, the FDA has rejected Forest Laboratories' bid to market Namenda as a treatment for mild Alzheimer's. Report

> Shares of ImmunoGen were on the rise this morning after it announced a new licensing deal with Genentech for its cancer-fighting agents. Story

> GlaxoSmithKline, Europe's biggest drug maker, launched Phase III clinical trials of a treatment for AIDS made by Ono Pharmaceutical. The drug, called ONO-4128/873140, will be administered to HIV-positive patients who already have been treated with other AIDS drugs. Ono licenses the drug to GlaxoSmithKline, which is expanding its line-up of AIDS treatments. Story

> Adventrx's NNRTI drug shows in-vitro power against resistant HIV. Release

> Valeant Pharmaceuticals plans to start Phase III trials of Retigabine, its first-in-class epilepsy drug. Release

> Serologicials subsidiary Chemicon International has inked a deal to commercialize research products based on patented human embryonic stem (ES) cell technology developed by Wisconsin Alumni Research Foundation. Release

> 454 Life Sciences receives $11.5 million in milestone payments from Roche. Release

> ImClone profit climbs on sales of its Erbitux cancer drug. Story

And Finally... Mars chocolatiers are in talks with biotechs to develop medical applications for cocoa flavanols. Report